Daclatasvir-sofosbuvir combination highly effective and well tolerated in patients with hepatitis C
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...
Apr 23, 2015
0
11